Phase 2
Completed N=42
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
Source: ClinicalTrials.gov NCT00125359 ↗Enrolled (actual)
42
Serious AEs
71.4%
Results posted
Nov 2018
Primary outcomePrimary: Radiographic Response Rates — 19 Participants
Summary
The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer.
Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Radiographic Response Rates |
19 | — |
| SECONDARY Correlation of Early PET Responses With Objective Radiographic Responses. |
1; 0; 0; 0; 0; 1 | — |
| SECONDARY Progression-free Survival and Overall Survival |
7; 22 | — |
| SECONDARY Evaluation of EGFR Mutations in Tumor Biopsies and Correlation of EGFR Mutations With Objective Radiographic Responses. |
0; 2; 1; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Advanced NSCLC
- Prior chemotherapy or radiotherapy is allowed.
Exclusion Criteria
- Hepatic or renal dysfunction
Data sourced from ClinicalTrials.gov (NCT00125359). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.